Participants were randomly assigned by web-based permuted block randomisation ( block size @ ) in a @:@:@:@ ratio to the four treatment groups : cisplatin ( @ mg/m ( @ ) intravenously on day @ or @ of the treatment cycle ) and paclitaxel ( @ mg/m ( @ ) intravenously over @ h or @ mg/m ( @ ) intravenously over @ h on day @ ) , with or without bevacizumab ( @ mg/kg intravenously on day @ or @ ) , or paclitaxel ( @ mg/m ( @ ) over @ h on day @ ) and topotecan ( @ mg/m ( @ ) for @ min on days @-@ ) with or without bevacizumab ( @ mg/kg intravenously on day @ ) .